The USPTO issues a Notice of Allowance to Alnylam Pharmaceuticals ( ALNY -0.5% ) for claims in the Tuschl et al. patent application 13/725,262. The 262 patent application includes claims directed
sector since the spring of this year, leading to unimpressive performance for leading RNAi companies Alnylam Pharmaceuticals (NASDAQ: ALNY ) and Isis Pharmaceuticals (NASDAQ: ISIS ). I won't try to argue that valuations didn't get overheated
Alnylam Pharmaceuticals reported second-quarter results that were largely consistent with our expectations, and we're maintaining our $66 fair value
of options issued as a percentage of shares outstanding, putting shareholders at risk for future dilution. Alnylam Pharmaceuticals is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class
Alnylam Pharmaceuticals , Inc. (NASDAQ: ALNY ) Q2 2014 Earnings Conference Call August 7, 2014 5:00 ..... Operator Good day ladies and gentlemen and welcome to the Alnylam Pharmaceuticals ’ Q2 2014 Earnings Conference Call. At this time all
Alnylam Pharmaceuticals ( ALNY -2% ) Q2 results : Collaboration Revenue: $7.3M (-16.0%); Operating Loss: ($45.0M) (-111.3%); Net Loss
The following audio is from a conference call that will begin on August 07, 2014 at 16:30 PM ET. The audio will stream live while the call is active, and can be replayed upon its completion. Listen now Complete Story »
Alnylam Pharmaceuticals (NASDAQ: ALNY ): Q2 EPS of -$0.63 misses by $0.08 . Revenue of $7.3M (-16.0% Y/Y) misses by $2.06M . Shares +1.3% . Press Release Post your comment!
The EMA's Committee for Orphan Medicinal Products designates Alnylam's (NASDAQ: ALNY ) ALN-AT3 an orphan drug for the treatment of hemophilia A and hemopholia B. ALN-AT3 is an RNA therapeutic that targets antithrombin . Post your comment!
By Life Sciences Report : A biotech analyst could play it safe, and stick with mid-, late- and commercial-stage companies that offer higher odds and decent returns on good news. Christopher James, on the other hand, recommends that investors willing to diversify their holdings and take on informed